Abstract: This disclosure provides compositions and methods for reducing or treating insulin resistance in a subject.

Abstract: This application relates to, inter alia, anti-cMET antibody drug conjugates (“ADCs”) having lower target-specific binding at low versus physiologic pH (“pH-ADCs”), pharmaceutical compositions including the pH-ADCs, methods of making the pH-ADCs, methods of selecting specific patient populations for cancer treatment with an anti-cMET PH-ADC, and methods of using the pH-ADCs to treat cancers, including cMET+/cMET-expressing or cMET-overexpressing cancers, particularly including cMET+/cMET-expressing or cMET-overexpressing non-small cell lung cancers (“NSCLCs”).

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides combinations and methods for improving liver function, e.g., in a subject having a liver disease or disorder, or treating or preventing a liver disease or disorder, e.g., with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for increasing myogenesis, increasing muscle protein synthesis, increasing muscle mass, improving muscle quality or enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle dysfunction. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides compositions and methods for reducing or treating insulin resistance in a subject.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.

Abstract: This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.